Message from CEO
It is with great pleasure that I welcome you to Spaulding Clinical where we are First in Phase I.
With a focus on the highest quality data, the highest standards of safety, and the most advanced technology the market has to offer, Spaulding Clinical delivers a truly unique clinical research solution that is being rapidly embraced by a growing list of pharmaceutical partners and biotech companies from around the world — companies who are now able to conduct larger scale studies more quickly and more cost-effectively than ever before.
At our facility in West Bend, Wisconsin, we operate a 200-bed Phase I clinical pharmacology unit (including 96 telemetry beds). Though we conduct studies of all kinds, we are experts in the conduct of TQT studies and have created the industry’s first fully-automated TQT study and analysis option. Because our unique setup, automated technologies, and engineered solutions applied so well to all types of complex Phase 1 trials, we expanded our business to offer full-service Phase I conduct, Biostatistics and Data Management, and Phase 1 Core ECG Laboratory services.
For all our customers worldwide, this means higher-quality data in less time and at a lower cost, all of which are a part of our greater mission:
Spaulding Clinical is passionate in their pursuit of ingenious solutions that save time and money for their clients and heroic in their ambitions to ensure the health and safety of patients. Spaulding Clinical strives to be a trusted partner in creating a world of safer drugs and a technology leader in pioneering new systems for conducting clinical research.
Today, our customers come back repeatedly due to our experience in making the complex simple. I encourage you to spend some time on our website where you will find more information on our unique approach to clinical trials and health care solutions. We are an innovative company that grows through following the time-tested tradition of listening to our customers.
CEO, Spaulding Clinical